pharmaphorum June 17, 2022
Phil Taylor

Walgreens is the latest US retail pharmacy giant to have a go at disrupting the clinical trials industry, with the launch of a new business unit that will tap into its reserve of patient data, as well as the ability to recruit patients across its retail network.

The company says it plans to use a “flexible” model, drawing on both decentralised trial (DCT) and conventional site-based models via its Health Corner and Village Medical outlets at various Walgreens locations across the US.

The move follows in the footsteps of rival chain CVS, which launched its clinical trials services business last year. Walgreens’ approach is very similar to CVS’ focus on DCT and hybrid trial, as well as use of its...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Clinical Trials, Pharma, Pharma / Biotech, Trends
Challenges in Trial Access and Treatment for Women with Chronic Illnesses
Brainomix AI shows its worth in AZ pulmonary fibrosis trial
Moderna moves three vaccines into final stage trials as it works to rebound from Covid slump
'From Interpretation to Action': Using CGM to Manage T2D
Oncology in 2024: The clinical trial trends reshaping the role of CROs

Share This Article